Newsgroup: it.economia.borsa
Titolo: cell?

vedo un +8,44. possibile?
... 


news in arrivo da Montecarlo ?

 ...
no, io vedo un -2,79% a 1.2910?
kikko 

 ha scritto nel messaggio 
news:4469858a$0$989$5fc...@news.tiscali.it...

vabbè, aspettiamo le 11 allora
e. 

 ha scritto nel messaggio 
news:4469858a$0$989$5fc...@news.tiscali.it...

ops... era il valore di chiusura di ieri
sorry, kikko 

 ...
-2,78% 

 ...
Pixantrone Produces High Rate (77 percent) of Complete Tumor
Disappearance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
 Substituting for Standard Anthracycline Chemotherapy May Offer Better
Chance
                            for Complete Remission
SEATTLE, May 16 /PRNewswire-FirstCall/ -- Preliminary results of a
phase I/II study of pixantrone combined with fludarabine,
dexamethasone, and rituximab for treatment of patients with relapsed
indolent non-Hodgkin's lymphoma (NHL) will be presented today at the
Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monte
Carlo, Monaco. The phase I/II study of the pixantrone combination
regimen, known as FPD-R, produced a 95 percent overall response rate
(ORR) with 77 percent of patients experiencing complete disappearance
of their tumors (complete remission). Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC) is also studying pixantrone in an ongoing phase
III study in aggressive NHL, known as the EXTEND trial.
In the phase I/II study, of the 22 patients evaluable for response, 95
percent achieved an objective response, including 77 percent who
achieved complete response/unconfirmed complete response (CR/CRu) with
18 percent achieving a partial response (PR). At two years, overall
survival is 85 percent, with a median failure-free survival of 25
months (range, three to 29 months). Predominant side effects (grade
3/4) were primarily hematological including neutropenia (76 percent),
febrile neutropenia (8 percent), lymphopenia (76 percent),
thrombocytopenia (20 percent) and anemia (4 percent).
"Although many regimens induce responses in patients with relapsed
indolent NHL, many of the remissions are of relatively short duration,"
noted Jack W. Singer, M.D. Chief Medical Officer at CTI. "These data
suggest that use of pixantrone with fludarabine, dexamethasone and
rituximab not only offers a very high response rate, but impressive
durability."
The webcast with slides will be available at 
www.cticseattle.com
.
About Pixantrone and the FPD-R Regimen
This trial examines the safety and potential efficacy for pixantrone
when substituted for mitoxantrone in the FND-R regimen (fludarabine,
mitoxantrone, dexamethasone, rituximab) for patients who had failed
prior treatment.
Patients received a median of 5.5 cycles of therapy. Cycles were every
28 days. Dosing was rituximab at 375 mg/m2 dl, fludarabine at 25
mg/m2/d d1-3, dexamethasone at 20 mg/d PO, d1-5 and pixantrone starting
at 80 mg/m2 to 120 mg/m2.
About Pixantrone
Pixantrone is an investigational agent under development for the
potential treatment of various hematological malignancies, solid tumors
and immunological disorders. It was developed to improve the activity
and safety of the anthracycline family of anti-cancer agents.
Anthracyclines have been shown to be very active clinically in a number
of tumor types. However, they are usually associated with cumulative
heart damage that prevents them from being used in a large proportion
of patients. Pixantrone has been designed to reduce the potential for
these severe cardiotoxicities, as well as to potentially increase
activity and simplified administration compared to the currently
marketed anthracyclines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at
making cancer more treatable. For additional information, please visit
www.cticseattle.com
.
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could
materially and/or adversely affect actual future results. Specifically,
the risks and uncertainties that could affect the development of
pixantrone include risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and with
pixantrone in particular including, without limitation, the potential
failure of pixantrone to prove safe and effective for treatment of
non-Hodgkin's lymphoma, determinations by regulatory, patent and
administrative governmental authorities, competitive factors,
technological developments, costs of developing, producing and selling
pixantrone, and the risk factors listed or described from time to time
in the Company's filings with the Securities and Exchange Commission
including, without limitation, the Company's most recent filings on
Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly
disclaims any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events, or
otherwise.
SOURCE  Cell Therapeutics, Inc.

 ...
Pixantrone Produces High Rate (77 percent) of Complete Tumor


ho dato un'occhiata alle slides, niente di stupefacente... adesso
guardo meglio

 ...
      Cell Th., 77% scomparsa tumore in studio preliminare Pixantrone
      Reuters - 16/05/2006 09:57:41
      MILANO, 16 maggio (Reuters) - Cell Therapeutics (CTIC.MI) (CTIC.O) 
comunica che i risultati preliminari di uno studio di fase I/II hanno 
mostrato che il pixantrone somministrato in regiMe di combinazione a 
pazienti affetti da linfoma non-Hodgkin
      recidivato (NHL) indolente determina la scomparsa completa del tumore 
nel 77% dei casi.
      Lo annuncia una nota della biotecnologica che sta valutando il 
pixantrone anche nell'ambito di uno studio di fase III nel NHL aggressivo.
      "La sostituzione della chemioterapia standard con antracicline può 
offrire una migliore possibilità di remissione completa", dice ancora la 
nota.
      Il pixantrone è un farmaco sperimentale in sviluppo per il trattamento 
potenziale di varie malattie ematologiche maligne. E' stato sviluppato per 
migliorare l'attività e la sicurezza degli agenti antitumorali appartenenti 
alla famiglia delle antracicline.

il fast track è per il pixantrone?

 il fast track è per il pixantrone?
Feb 08, 2006
XYOTAXTottiene da FDA la designazione Fast Track per il trattamento
delle donne affette da tumore polmonare avanzato con stato di
performance ridotto (PS2)

fonte e data?

 fonte e data?
La data è scritta e la fonte è il sito di CTIC... ;-)

basta parlare di xiotax... stanno ancora cercando un global partner
Pixantrone: non solo per linfoma
Pixantrone: fast track
correggetemi se sbaglio

http://www.finanza.com/News/%7BE0AEF409-37EB-414F-AF7C-6BC32EE6E52F%7D.asp
 

 il fast track è per il pixantrone?
anche il Pixantrone ha il fast track

scometto che tu le hai vendute ieri...


590 + 590  pm 4.5 stop 

 anche il Pixantrone ha il fast track
Sorry, nel loro sito non l'ho trovato...

 anche il Pixantrone ha il fast track
Sorry, nel loro sito non l'ho trovato...
Cell Therapeutics Receives Fast Track Designation for Pixantrone for the
Potential Treatment of Aggressive Non-Hodgkin's Lymphoma
      Designation Granted on Basis of Responses Observed in Phase 2 Trials
      SEATTLE, Jul 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- Cell
Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato: CTIC) received fast
track designation from the U.S. Food and Drug Administration (FDA) for
pixantrone, a novel anthracenedione, being investigated for the potential
treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL). The FDA
granted fast track designation because relapsed aggressive NHL in the
third-line or subsequent recurrence is a life threatening disease and
responses have been noted in phase 2 trials in patients with relapsed,
aggressive NHL. Preliminary experience in phase I/II studies of pixantrone
has shown a complete remission rate ranging from 20 percent as a
single-agent to 59 percent in a variant of the standard front-line
combination therapy CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone), where pixantrone replaces doxorubicin. In addition, pixantrone
is easier to administer than standard anthracyclines and, to date, has not
displayed the same risk of severe cardiac damage.
      "The complete remission rates of single-agent pixantrone and in
combination with other agents in phase I and phase II clinical studies are
quite remarkable. As there are currently no approved therapies for
third-line aggressive non-Hodgkin's lymphoma (NHL) we expected to obtain
'fast track' designation for this product," stated Jack W. Singer, M.D.,
Chief Medical Officer of CTI. "The pivotal trial is well-designed and if
successful, the efficacy and cardiac safety profile along with the drug's
administration advantages may make pixantrone an important therapeutic for
the potential treatment of aggressive NHL."
      "Fast track designation for pixantrone is an important step in the
development of this product candidate and may help us bring this potentially
life-saving drug to patients more quickly," stated James A. Bianco, M.D.,
President and CEO of CTI.
      Pixantrone is presently being studied as a single-agent and in
combination in several phase I and II clinical studies for the potential
treatment of aggressive or indolent NHL. In the United States, it is
estimated that more than 30,000 patients each year receive salvage therapy
for salvage NHL (greater-than-or-equal-to third-line) with more than 60,000
patients receiving multi-agent chemotherapy for front-line or second-line
treatment of NHL.
      Fast Track Designation
      Fast track designation provides the FDA with mechanisms to help
facilitate the development and expedite the review of a new drug that is
intended to treat a serious or life-threatening condition and demonstrates
the potential to address an unmet medical need. Due to the nature of these
types of products, new drug applications (NDAs) filed with Fast track
designation are eligible for priority review, which provides for review of
the NDA within six months.